Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.8
Journals
Healthcare
Special Issues
Innovative Treatments for Post-traumatic Stress Disorder (PTSD)
share announcement

Innovative Treatments for Post-traumatic Stress Disorder (PTSD)

A special issue of Healthcare (ISSN 2227-9032).

Deadline for manuscript submissions: 31 July 2024 | Viewed by 3758

Special Issue Editor

Prof. Dr. Wissam El-Hage

E-Mail Website
Guest Editor
Regional Trauma Center, UMR 1253 iBrain, Clinical Investigation Center CIC1415, CHRU de Tours, Université de Tours, INSERM, Tours, France
Interests: PTSD; treatment-resistant depression; PNES
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Post-traumatic stress disorder (PTSD) is a trauma-related mental health condition triggered by experiencing or witnessing a frightening or distressing event. PTSD is prevalent in high-income countries (up to 10% of lifetime prevalence), is twice more common in females than in males, and co-occurs with other psychiatric disorders and physical conditions. Symptoms may include flashbacks, nightmares, avoidance, severe anxiety, negative changes in thinking and mood, and changes in physical and emotional reactions with considerable functional impairment. In recent decades, effective evidence-based treatments for PTSD have been developed. In spite of these encouraging developments, finding effective, relevant, and personalized treatments for patients with PTSD, including  all types of trauma and post-traumatic morbidities, remains challenging. 

We are pleased to invite you to contribute to this Special Issue, ‘Innovative treatments for post-traumatic stress disorder (PTSD)’, which welcomes original research articles and reviews that either (i) describe successful prevention strategies and/or early interventions, (ii) promote effective programs to increase resilience to war-related or civilian-related trauma, (iii) describe innovative therapeutic strategies, (iv) evaluate the effectiveness of conventional or innovative psychotherapeutic treatments, or (v) evaluate the effectiveness of pharmacotherapeutic treatments and strategies for PTSD. 

The goal of this Special Issue is to foster innovation and the more widespread use of evidence-based approaches, and to share insights obtained from field experience, inter-cultural views, and academic knowledge, in order to enhance access to care for PTSD. 

I look forward to receiving your contributions.

You may choose our Joint Special Issue in Brain Sciences.

Prof. Dr. Wissam El-Hage
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • trauma
  • PTSD
  • therapy
  • prevention
  • innovation
  • resilience
  • policies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 1586 KiB  
Article
Clinical Efficiency and Acceptability of EMDR and MOSAIC Therapy for PTSD
by Deborah Flatot-Blin, Arnaud Rey, Flavie Derynck, Olivier Fossard and Stephanie Khalfa
Healthcare 2023, 11(15), 2226; https://doi.org/10.3390/healthcare11152226 - 07 Aug 2023
Cited by 1 | Viewed by 2203
Abstract
Eye movement desensitization and reprocessing (EMDR) therapy is one of the therapies recommended by the World Health Organization (2013) to treat posttraumatic stress disorder (PTSD). Although efficient, repeated exposure to the traumatic memory may reduce its acceptability to patients. The therapy “eye movement [...] Read more.
Eye movement desensitization and reprocessing (EMDR) therapy is one of the therapies recommended by the World Health Organization (2013) to treat posttraumatic stress disorder (PTSD). Although efficient, repeated exposure to the traumatic memory may reduce its acceptability to patients. The therapy “eye movement and alternate stimulation for brain integration” (MOSAIC in French) was developed to improve acceptability and reduce pain by drawing on the patient’s internal resources. MOSAIC therapy focuses on the body sensations that the patient wants to experience and avoids having to relive the traumatic memories. This observational study aimed to compare the clinical efficiency of EMDR and MOSAIC therapy for PTSD and to measure the well-being generated by both therapies. Twenty-six PTSD patients (17 females and 9 males, mean age 37.01 years, SD = 13.06) received treatment by psychiatrists and/or psychologists trained with EMDR or MOSAIC therapy. Both patient groups achieved a significant decrease in PTSD symptoms as measured with the PCL-5. However, fewer sessions were required with the MOSAIC therapy than with EMDR therapy. As expected, the level of well-being experienced by the patient during the therapy, assessed using the Lickert scale, was higher with MOSAIC than with EMDR therapy from the first session. These findings provide the first evidence of the efficacy of MOSAIC therapy treatment, which now needs to be corroborated in a larger randomized clinical trial. Full article
(This article belongs to the Special Issue Innovative Treatments for Post-traumatic Stress Disorder (PTSD))
►▼ Show Figures

Graphical abstract

Other

Jump to: Research

13 pages, 614 KiB  
Study Protocol
July 14th 2016 Nice Terrorist Attack Court Trial: A Protocol on Sleep Quality and Somatic Symptoms as Markers of Risk for Traumatic Reactivation in Adolescents Exposed to This Attack
by Radia Zeghari, Morgane Gindt, Jokthan Guivarch, Philippe Auby, Philippe Robert, Julie Rolling, Carmen Schröder, Petri Valo, Florence Askenazy and Arnaud Fernandez
Healthcare 2023, 11(22), 2953; https://doi.org/10.3390/healthcare11222953 - 12 Nov 2023
Viewed by 876
Abstract
The court trial of the 14th of July 2016 terrorist attack in Nice (France) opened in September 2022 and ended in December 2022. Engaging in court proceedings, whether as a victim or a witness, can lead to a significant risk of traumatic reactivation [...] Read more.
The court trial of the 14th of July 2016 terrorist attack in Nice (France) opened in September 2022 and ended in December 2022. Engaging in court proceedings, whether as a victim or a witness, can lead to a significant risk of traumatic reactivation (i.e., the re-emergence of post-traumatic stress symptoms). The present protocol aimed to improve knowledge of the pathophysiology of traumatic reactivation due to the media coverage of the trial by assessing sleep disturbances and somatic symptoms that could reappear if there is a traumatic reactivation. Method and Analysis: This is a monocentric longitudinal study, with recruitment solely planned at the Nice Pediatric Psychotrauma Center (NPPC). We intended to include 100 adolescents aged 12 to 17 years who were directly or indirectly exposed to the attack and included in the “14-7” program). Assessments began one month before the trial, in August 2022, and were scheduled once a month until the end of the trial. A smartwatch recorded sleep activity. Somatic and PTSD symptoms and sleep were assessed through validated questionnaires. The main analyses comprised the variance and regression analyses of predictors of clinical evolution over time. Ethics and Dissemination: The National Ethics Committee “NORD OUEST III” approved the “14-7” program protocol (number 2017-A02212-51). The specific amendment for this research was approved in April 2022 by the same national ethical committee. Inclusions started in August 2022. Full article
(This article belongs to the Special Issue Innovative Treatments for Post-traumatic Stress Disorder (PTSD))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop